Exploring Novel Vulnerabilities for Type II RAF Inhibitors in Living Cells With NanoBRET

Time: 11:30 am
day: Day One Track A AM


  • New NanoBRET assay technology to quantify type II RAF inhibitor occupancy at individual protomers within RAS/RAF complexes
  • Compared to BRAF and CRAF, clinical-stage drugs escape ARAF inhibition in cells
  • Additional application of NanoBRET technology to study conformation-selective DFG-OUT inhibitors across the broader kinome